A novel class of antithrombotic medication, the factor XIa inhibitors, has had a rocky start but is powering through phase III trials, which are now underway. MedPage Today sat down to discuss the ...

The coagulation cascade is a finely balanced system essential for maintaining haemostasis, yet its disruption can lead to either a propensity for bleeding or an increased risk of clot formation.

Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pfizer has earned a nod from the U.S. regulator for another of its products in the indication. On Friday, the FDA signed off ...

Concizumab-mtci (Alhemo) is approved for hemophilia A or B with inhibitors, offering a subcutaneous alternative to intravenous treatments. The phase 3 explorer7 trial demonstrated an 86% reduction in ...

Study demonstrates superiority, showing both statistically significant and clinically meaningful reduction in annualized bleeding rate with a generally well-tolerated safety profile compared to ...

Findings showed concizumab-treated patients had an 86% reduction in annualized bleeding rate compared with no prophylaxis. The Food and Drug Administration (FDA) has approved Alhemo ® (concizumab-mtci ...

The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and adolescents ages 12 years and older with hemophilia A without factor VIII ...